Enhancing Chemotherapy in Colon Cancer with BAL9611
Author Information
Author(s): Paolo A Di, Danesi R, Caputo S, Macchia M, Lastella M, Boggi U, Mosca F, Marchetti A, Tacca M Del
Primary Institution: Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, University of Chieti, Italy
Hypothesis
Inhibition of protein farnesylation enhances the efficacy of the geranylgeranyltransferase inhibitor BAL9611 in treating colon cancer.
Conclusion
Inhibition of protein farnesylation improves the effectiveness of BAL9611 in treating colon cancer both in the lab and in live models.
Supporting Evidence
- BAL9611 and manumycin inhibited SW620 cell growth in a dose-dependent manner.
- The combination of BAL9611 and manumycin was found to be highly synergistic.
- Both drugs induced cell death by apoptosis in vitro and in vivo.
Takeaway
This study found that using two drugs together can help fight colon cancer better than using just one.
Methodology
The study evaluated the effects of BAL9611 and manumycin on the SW620 human colon cancer cell line and in CD nu/nu female mice.
Participant Demographics
CD nu/nu female mice were used in the in vivo part of the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website